Nazione: Canada
Lingua: inglese
Fonte: Health Canada
CONJUGATED ESTROGENS
WYETH CANADA
G03CA57
CONJUGATED ESTROGENS
0.9MG
TABLET
CONJUGATED ESTROGENS 0.9MG
ORAL
30/100
Prescription
ESTROGENS
Active ingredient group (AIG) number: 0106442007; AHFS:
CANCELLED POST MARKET
2007-08-13
_Premarin_ ® _ (conjugated_ _ _ _estrogens tablets, CSD) _ _Page 1 of 42_ PRODUCT MONOGRAPH Pr PREMARIN ® (conjugated estrogens tablets, CSD) 0.3 mg, 0.625 mg, 0.9 mg, and 1.25 mg ESTROGENIC HORMONES © Wyeth Canada. 1025 Marcel Laurin Blvd. St. Laurent (Montreal), Quebec Canada H4R 1J6 Date of Revision: June 01, 2007 Submission Control No: 109700 _Premarin_ ® _ (conjugated_ _ _ _estrogens tablets, CSD) _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS..................................................................................................13 DRUG INTERACTIONS ................................................................................................18 DOSAGE AND ADMINISTRATION..............................................................................21 OVERDOSAGE ................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ............................................................23 STORAGE AND STABILITY..........................................................................................26 SPECIAL HANDLING INSTRUCTIONS .......................................................................26 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................26 PART II: SCIENTIFIC INFORMATION ...................................................................28 PHARMACEUTICAL INFORMATION....................................................................... Leggi il documento completo